Yesterday, Amgen announced that it would launch the U.S.’s first marketed Humira-referenced biosimilar, Amjevita (adalimumab-atto), at two different list prices: $3,288 and $1,557 per 40 mg pen ...

As such, Cyltezo may gain a distinct marketing advantage over other Humira-referenced biosimilars, such as Amjevita and soon to launch Yusimry. This month, five more Humira biosimilars are ...

UnitedHealth (UNH) said Amgen's (AMGN) Humira biosimilar Amjevita will be among the alternatives available on its lists for commercial health plans operated by its pharmacy benefit manager (PBM ...